Pramlintide (AC0137, AC137, triPro-amylin) is a synthetic antidiabetic peptide that corresponds to human amylin (aa34-70) with proline substitutions at N25, S28 and S29 to limit the self-aggregation seen with native amylin. Pramlintide augments endogenous amylin-mediated glycemic control (blood glucose regulation) in vivo by delaying gastric emptying and inhibiting the secretion of glucagon, a catabolic hormone that opposes the effects of insulin and amylin.
